If you or someone you know dreads pollen season, here’s something worth knowing: the conversation around hay fever (allergic rhinitis) is shifting beyond just symptom relief toward actually retraining the immune system.
The usual approach — antihistamines and steroid nasal sprays — calms symptoms but doesn’t change how the body reacts to allergens long-term.
Immunomodulators work differently. Allergen immunotherapy, a form of immunomodulation, gradually exposes the immune system to small amounts of an allergen so it becomes desensitized over time. It allows the immune system to “get used to” the allergen, which can relieve symptoms, and it’s suitable for people allergic to tree, weed, and grass pollen . It’s currently considered the only available treatment that can be curative rather than just symptom-masking.
A 2025 clinical study comparing the two approaches found meaningful real-world benefits: patients receiving immunomodulatory therapy had significantly fewer rhinitis recurrences than those on conventional treatment alone .
Science is also moving into newer territory. Researchers are increasingly exploring biologics that target specific immune pathways involved in allergic inflammation , and in early 2025 China approved the first global IL-4Rα antagonist for seasonal allergic rhinitis  — a sign of where treatment may be headed.
Takeaway: for the right candidates, immunomodulation isn’t just about getting through allergy season — it’s about changing the trajectory of the allergy itself.
References:
1. Medicine Journal (2025), DOI: 10.1097/MD.0000000000042244
2. InformedHealth.org / NCBI Bookshelf
3. PMC, Int J Mol Sci. 2025 May 9;26(10):450
